High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs - Test2 - elhamkhani - TriplyDB

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

http://www.wikidata.org/entity/Q24644255

about

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Cytotoxic and targeted therapy for hereditary cancers Targeting DNA Replication Stress for Cancer Therapy The biological effects and clinical implications of BRCA mutations: where do we go from here?New treatment option for ovarian cancer: PARP inhibitors Trial watch - inhibiting PARP enzymes for anticancer therapy Role of Biomarkers in the Development of PARP Inhibitors The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms Biomarkers in triple negative breast cancer: A review Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer PARP inhibitors in the management of breast cancer: current data and future prospects Profile of veliparib and its potential in the treatment of solid tumors Current approaches in treatment of triple-negative breast cancer PARPs and the DNA damage response The role of PARP in DNA repair and its therapeutic exploitation Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers Targeting DNA damage response in cancer therapy PARP inhibitors and more Current status and evolution of preclinical drug development models of epithelial ovarian cancer A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors Femtosecond near-infrared laser microirradiation reveals a crucial role for PARP signaling on factor assemblies at DNA damage sites.Fine tuning chemotherapy to match BRCA1 status Novel therapeutic strategies for patients with triple-negative breast cancer PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment Genetically engineered mouse models in oncology research and cancer medicine New perspectives on targeted therapy in ovarian cancer Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer PARP inhibitor treatment in ovarian and breast cancer PARP inhibition: PARP1 and beyond

P2860

Q21129302-CA7C300D-8B08-4291-BF01-488F1CBBC5F1 Q24302687-BE5DA369-B083-409E-9309-C9B70C8B4223 Q24599364-B0C983FC-70EC-4679-A5E7-B894D03DC865 Q24600350-762EFB1B-8EC0-4CA6-8851-3C8D91CE4C7F Q24632628-2A27E4B8-0AA0-4EDE-BFEF-5F14C97391F2 Q24657145-77C0A2CF-DB28-4B36-88C4-035FA3D131E1 Q26739366-C8525CCE-F870-41F7-84C8-206A9C643E56 Q26739923-58DE09D1-1317-47CE-B30A-524A959FFB14 Q26741851-BD5C4415-564E-4899-A1F4-FF9BE6FD8BD3 Q26745614-BBCA4C65-D5C7-485E-A8C0-07BD6A86682F Q26745673-1905513C-E95D-46B4-B6BA-DD3B6B975890 Q26753159-AB3626B8-2F72-4357-8486-CBBEE6AD7A6D Q26765247-34CA6837-DFA2-48F1-863B-5F7A2DE76949 Q26775094-6D03F3E3-1E56-4D7A-BAD8-2D1544696A58 Q26783551-0F61CAA3-DBAE-4404-BAFB-630ACA5E97F5 Q26798352-04021CD1-2C41-4AEC-93C5-EB7B119019DB Q26801272-EE359148-51CB-4ABC-BEEB-2CD7BEE49031 Q26801549-49345430-9C05-419F-B57E-33BD048C2258 Q26859010-49D38CA3-CCA1-48F7-872E-04FA31B94034 Q27002399-C2DA94DF-5FC4-485C-9F93-D9F991ACB98A Q27006938-4F27A066-06F6-47B1-A744-08748C091D1B Q27023204-9A452785-809B-4546-908A-B4563D785BCA Q27027014-F8A1DE4E-FA89-43CD-A93A-1460C46F6F50 Q27028117-08087B0F-B3A7-4A98-88A1-88206C491D29 Q27302763-2104468E-CC16-4A27-9C8C-9B2259F70E4B Q27318449-5078AB47-9076-47D2-B6BE-4CAC1C80E19B Q27324256-498E840B-4E2E-4D4F-9294-8BB12DF67AE6 Q27694529-D08800DC-F079-4263-80B9-AE321C786C66 Q28067436-6775906A-B62B-4F89-9C39-E4C83846C424 Q28071345-1161C639-431C-4D9E-9BAD-5989C9D5D422 Q28072204-FCD5F627-62A3-4FC5-83C4-96F4AF6D272D Q28075761-EA9FA4B2-649E-4685-B58F-ABD50F542B21 Q28079323-AA991C42-7895-403A-8256-66DDFC70EA93 Q28082524-C171BD0A-40D9-4DD3-975C-367AAD313619 Q28262260-6416C6FC-9EF4-4D6D-9565-B029ED498D53 Q28282860-1A93D6ED-C74E-49A5-B736-9FBA706AA403 Q28304985-513FF9FB-5ED2-470C-A85D-5A417B1C2C6E Q28538059-FEB5D1C1-8F91-4FAA-A39E-AA236CE01B06 Q28741688-9F64F9E6-E4EB-4BB8-BCBC-6A4F3C6C2AE0 Q29619617-F1E8FE52-1A73-49BF-A85D-33B1AF61149C

P2860

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

http://www.wikidata.org/entity/Q24644255

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

High sensitivity of BRCA1-defi ...... ombination with platinum drugs

@ast

High sensitivity of BRCA1-defi ...... ombination with platinum drugs

@en

High sensitivity of BRCA1-defi ...... ombination with platinum drugs

@nl

type

label

High sensitivity of BRCA1-defi ...... ombination with platinum drugs

@ast

High sensitivity of BRCA1-defi ...... ombination with platinum drugs

@en

High sensitivity of BRCA1-defi ...... ombination with platinum drugs

@nl

prefLabel

High sensitivity of BRCA1-defi ...... ombination with platinum drugs

@ast

High sensitivity of BRCA1-defi ...... ombination with platinum drugs

@en

High sensitivity of BRCA1-defi ...... ombination with platinum drugs

@nl

P1433

Q24644255-CD333F8F-1E77-47F8-B129-92AC20AAF96B

P1476

Q24644255-BB0C9E65-EF4B-4E11-BC5C-FFAB8DA95F04

P2093

Q24644255-1E1CF2BE-02E6-46E5-B77A-3BF7BA97A1C4

Q24644255-46D370AE-DB23-412E-BDBE-C6B1BFAD8ECE

Q24644255-5623BF4B-5FC9-42F3-AB53-268A52B389FB

Q24644255-626F230B-F330-4A2B-B1F0-EF681E68DDCB

Q24644255-7BD08F92-0FB7-4FE0-8078-62766A923233

Q24644255-80FD0F40-D67B-474D-9B75-ECD7498E05E8

Q24644255-8C8B7023-8EB5-4E5A-9FC8-DADBBEDBE5A6

Q24644255-924A4130-DC81-4EC8-8178-40C1E29201AC

Q24644255-93CDA25A-92BB-4C80-B11A-CE8E7C1727F4

Q24644255-A54AB176-FBB6-48E5-A465-99FA7399E3F7

P2860

Q24644255-1A1203DB-B92C-4F8F-B42B-AF8DBFB12A2A

Q24644255-20B74EB2-9C39-4E08-88D6-9145912D06C8

Q24644255-31F3A541-34B7-4D2C-9CB0-0D21AB1FCC33

Q24644255-38282B04-826C-4286-9CE1-F68E8CBB4EF7

Q24644255-3EB9FE8A-A2FB-4C9C-8F7D-3DD91AD62D16

Q24644255-40B1C347-6154-44D7-8A4A-EA1881596608

Q24644255-4175E461-AA48-4172-BAFC-C17AB9F4FBBE

Q24644255-46E4EE1A-F908-4E0E-841D-5076BAC353A3

Q24644255-47A2C47F-974B-4422-B29E-52EA38B7130C

Q24644255-4D87AEE0-D49D-4A5A-ABBD-6C283C2505F8

P304

Q24644255-42E3344A-269A-43F4-81F2-2DBB94168CF1

P31

Q24644255-71D35B6F-AB25-48FB-8E9E-7CBC4414ACA5

P3181

Q24644255-5A2DA819-0980-40FA-BE27-BD9F9EC60C53

P356

Q24644255-96C6255B-510D-497A-83B7-836BED9BE32C

P407

Q24644255-DFFDF6F8-02B1-40F6-A9B2-3C017695F46F

P433

Q24644255-7AFC2984-2480-4040-9F6E-3C581EFA23E2

P478

Q24644255-9AE3F04F-A2B2-46BA-AD8E-5FE0B67AE6C4

P50

Q24644255-9AD7A12E-E6C3-4E76-B9CA-D49867206EAF

P577

Q24644255-B0BC3E5A-2368-48BA-BC71-0CF6284D3EB2

P5875

Q24644255-2F5C013E-C8F5-4022-B74D-33609ED9B402

P698

Q24644255-D1169979-6821-4455-84C6-87016FD07607

P932

Q24644255-C685916A-D3DC-41DA-B0B5-B574D4E4DACF

P3181

P356

PNAS.0806092105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

High sensitivity of BRCA1-defi ...... ombination with platinum drugs

@en

P2093

Aaron Cranston

http://www.w3.org/2001/XMLSchema#string

Alan Lau

http://www.w3.org/2001/XMLSchema#string

Anders O H Nygren

http://www.w3.org/2001/XMLSchema#string

Ariena Kersbergen

http://www.w3.org/2001/XMLSchema#string

Eline van der Burg

http://www.w3.org/2001/XMLSchema#string

Janneke E Jaspers

http://www.w3.org/2001/XMLSchema#string

John Zevenhoven

http://www.w3.org/2001/XMLSchema#string

Jos Jonkers

http://www.w3.org/2001/XMLSchema#string

Mark J O'Connor

http://www.w3.org/2001/XMLSchema#string

Michiel de Bruin

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Resistance to therapy caused by intragenic deletion in BRCA2

DNA repair pathways as targets for cancer therapy

Poly(ADP-ribose): novel functions for an old molecule

Hallmarks of 'BRCAness' in sporadic cancers

In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

BRCA1 and BRCA2: 1994 and beyond.

P304

17079-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

604569

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.0806092105

http://www.w3.org/2001/XMLSchema#string

P407

P433

44

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Sven Rottenberg

P577

2008-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23438965

http://www.w3.org/2001/XMLSchema#string

P698

18971340

http://www.w3.org/2001/XMLSchema#string

P932

2579381

http://www.w3.org/2001/XMLSchema#string